Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) EPS (Basic) (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of EPS (Basic) data on record, last reported at -$0.11 in Q3 2025.

  • For Q3 2025, EPS (Basic) fell 320.0% year-over-year to -$0.11; the TTM value through Sep 2025 reached -$0.45, up 40.0%, while the annual FY2024 figure was -$0.49, 66.89% up from the prior year.
  • EPS (Basic) reached -$0.11 in Q3 2025 per SGMO's latest filing, down from -$0.08 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.13 in Q1 2023 and bottomed at -$0.66 in Q2 2023.
  • Average EPS (Basic) over 5 years is -$0.25, with a median of -$0.29 recorded in 2022.
  • Peak YoY movement for EPS (Basic): plummeted 3200.0% in 2021, then soared 143.33% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.25 in 2021, then decreased by 28.0% to -$0.32 in 2022, then fell by 12.5% to -$0.36 in 2023, then skyrocketed by 66.67% to -$0.12 in 2024, then grew by 8.33% to -$0.11 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.11 in Q3 2025, -$0.08 in Q2 2025, and -$0.14 in Q1 2025.